SOCS1 and colorectal carcinoma: Jover and colleagues used pyrosequencing to analyze an alternative panel of five markers (i.e., CACNAG1, SOCS1, RUNX3, NEUROG1, and MLH1) in CRC patients receiving 5-FU adjuvant therapy [52].